Introduction
Stigma was defined by Link and Phelan (2001) as a social process that is observed when there are elements of labeling, stereotyping, and discrimination because of characteristics previously specified as different and unacceptable, which result in social status loss. 1 Health-related stigma is based on a special characteristic of a health problem or a state. 2 Stigma worries the patient more than the disease itself, makes the patient feel guilty, and is associated with depression. 3 In patients with epilepsy, stigma is a result of the unpredictability of seizures and social exclusion due to a negative attitude of society, including difficulties in education, having a family, and finding a job, even when it is not contraindicated. 4 Because of stigmatization, patients hide the disease from relatives, partners, and employers. 5 The frequency of stigmatization varies from 31% to 54%, and in 9% to 29.3% of patients, it is severe. 3 In persons with epilepsy, perceived stigma (i.e., feelings of devaluation, shame, secret, or withdrawal caused by applying negative stereotypes to the subject) has been investigated most frequently by means of appropriate questionnaires. Epilepsy has a great influence on the three levels of quality of life (physical, mental and social health), an influence that is exercised directly by affecting physical and mental health and indirectly by introducing limitations and decreasing the opportunities for taking part in quality of life improving activities. The results from a number of studies have proven that the stigmatization in this group of patients is one of the factors contributing to quality of life decrease. [6] [7] [8] [9] No study of stigma and its impact on the quality of life of patients with epilepsy has been performed in Bulgaria.
Purpose of the study
Assessment of the impact of perceived stigma on the quality of life of Bulgarian patients with refractory epilepsy.
patients with pharmacosensitive epilepsy who attended the Clinic of Neurology at the University Hospital in Plovdiv, Bulgaria for a regular examination, for cases of unsatisfactory seizure control or for adverse events from treatment.
All study procedures were performed after the approval of the Local Ethics Commission at the University of Medicine, Plovdiv. Every patient was introduced to the study design and signed an informed consent form before participation in study procedures.
We used the following inclusion criteria: a signed informed consent form; age between 18 and 65 years; a diagnosis of refractory epilepsy; lack of cognitive impairment based on Evaluation Rapide des Fonctions Cognitives (ERFC; Gil and Toullat, 1986), with a score <47 in patients up to 60 years of age and primary education or <46 in patients between 60 and 65 years of age and less than a primary education or illiterate; lack of progressive somatic or neurological disease; lack of simple or complex partial seizures in the last 4 h; and lack of generalized tonic-clonic seizures in the last 24 h. We accepted epilepsy as refractory in cases in which adequate seizure control with at least two potentially effective antiepileptic drugs prescribed as monotherapy or combination at maximal tolerated doses had not been achieved. After excluding 39 patients with pseudo-refractory epilepsy (in cases with diagnostic, therapeutic errors or poor compliance), 2 patients older than 65 years, 2 patients with progressive neurological disease, 5 patients with a simple or complex partial seizures in the last 4 h or a generalized tonic-clonic seizure in the last 24 h, and 58 patients with cognitive impairment, 70 patients with refractory epilepsy and 70 patients with pharmacosensitive epilepsy remained in the study.
The data were collected through an interview and examination of the patients' medical documentation.
Twenty one (30.0% AE 5.5) of the participants with refractory epilepsy were men; the remaining 49 (70.0% AE 5.5) were women. The mean patient age was 41.7 AE 1.1 years. Most participants (76.6%) were between 30 and 60 years of age. The mean disease duration was 25.1 AE 1.3 years. Of the patients with pharmacosensitive epilepsy, 34 (48.6%) were men, and 36 (51.4%) were women; their mean age was 36.7 AE 1.5 years. There was no significant difference between both groups regarding their gender (P > 0.05, x 2 = 2.4) and age (P > 0.05, u = 0.6).
Patients with refractory epilepsy and pharmacosensitive epilepsy completed the stigma scale (MD Hyman, 1971); a Health Related quality of life measure (the QOLIE-89) was completed only by patients with refractory epilepsy. The stigma scale consists of three questions pertaining to patients' opinions about the attitudes of people. The possible answers are ''yes'' and ''no.'' The severity of perceived stigma depends on the number of positive answers. If there is one affirmative response, we accepted the patient as stigmatized. The scale scores are as follows: 0 = ''none'', 1 = ''mild'', 2 = ''moderate'', and 3 = ''severe''. The scale has been applied by Jacoby et al. 1 in patients with epilepsy, and is known to have satisfactory convergent validity and internal consistency.
2 QOLIE-89 is the most understandable and most widely used instrument for quality of life assessment in patients with epilepsy. It is the scale that includes the greatest number of epilepsyassociated factors. QOLIE-89 has been approved for research, and it is completed in 45 min. This scale enables the discrimination of minimally expressed but significant life quality changes in these patients. QOLIE-89 contains 89 items that are distributed in 17 subscales, characterizing 4 basic factors directed toward epilepsy, physical, mental, and social health. Except for the standard scores, the so-called ''G-scores'' for each of the 17 scale final scores and the overall score are calculated. The T-scores represent linear transformations of the scores that produce a mean of 50 and a standard deviation of 10 for the cohort of 304 adults with epilepsy. Higher T-scores reflect a more favorable quality of life.
In the course of the study, we made a validation of the Bulgarian translation of QOLIE-89 and proved its reliability, internal consistency (the mean of Crohnbach's a was 0.9 AE 0.0; the coefficient of Spearman-Brown was 0.9; the mean inter-item correlation was 0.3; we calculated a high coefficient of correlation between the subscales scores and the overall score in two completions of the questionnaire [r xy = 0.8-1.0]) and validity (strong correlations between the overall scores of QOLIE-89 and QOLIE-31 [r xy = 0.9] and between their corresponding subscales were found [r xy = 0.9-1.00]). 10 The collected primary information was checked, encoded, and entered into a computer database for statistical analysis. Data were processed using STATA Version 10 (Stata Corp., College Station, TX, U.S.A.) and SPSS (Statistical Package for the Social Sciences), version 14.0 (SPSS Inc., Chicago, IL, USA). The results for quantitative variables were expressed as the mean AE SE (standard error), and the results for qualitative variables were expressed as percentages AE SE. Age, gender, clinical findings, stigmatization of patients with refractory and pharmacosensitive epilepsy, as well as the assessments of the subscales and the overall score of QOLIE-89 made by stigmatized and non-stigmatized patients, were compared by means of x 2 -test and Z-test. Spearman coefficient (r s ) was used to analyze the correlation between stigma and the assessments of the subscales, as well as the overall score of QOLIE-89. Pairwise comparisons between the scores of the non-stigmatized patients and those of the mildly to moderately stigmatized patients were performed according to the Hochberg procedure to maintain an overall 5% type I error.
Results

Clinical findings of study participants
The clinical findings of the study participants are shown in Table 1 .
Perceived stigma of study participants
According to the results from the stigma scale, 26 (37.1%) of the patients with refractory epilepsy reported stigmatization. Seven (10%) of all participants with refractory epilepsy were mildly stigmatized, 3 (4.3%) were moderately stigmatized, and 16 (22.9%) were severely stigmatized. Only 4 (5.7%) patients with pharmacosensitive epilepsy were mildly or moderately stigmatized. There were no participants with both pharmacosensitive epilepsy and severe stigmatization. With respect to the perceived stigma, a significant difference between patients with refractory and pharmacosensitive epilepsy was demonstrated (P < 0.001, x 2 = 23.0).
QOLIE-89 results
The mean overall score of QOLIE-89 given by the patients with refractory epilepsy was 64.3 AE 17.1. In our data analysis, the Tscores were used for a more explicit comparison with the mean scores of the epileptic population. The obtained scores were accepted as very low ( 35), low (36-45), medium (46-55) and high (>55). As a Tscore, the mean overall score of QOLIE-89 was lower than the mean of the epileptic population (x = 47.8). Low mean scores were obtained for the subscales ''Health perceptions'' (x = 39.4), ''Sexual relations'' (x = 42.5) and ''Overall quality of life'' (x = 42.8). The mean scores of all other subscales were close to the mean of the epileptic population.
The subscales of QOLIE-89 were distributed in the following 5 groups: subscales associated with physical health, subscales associated with mental health, subscales associated with social health, subscales associated with epilepsy, and subscales associated with a more general assessment, e.g., ''overall health'' and ''overall quality of life''. For the purpose of data analysis, the overall QOLIE-89 score was also included in the last group.
QOLIE-89 results of the stigmatized and non-stigmatized patients
The distribution of the patients with refractory epilepsy with and without perceived stigma according to the scores of the subscales and the overall score of QOLIE-89 is presented in Fig. 1 .
Impact of perceived stigma on physical health
The perceived stigma has an impact on most aspects of the physical health, except for the subscales ''change in health'' (x 2 = 0.9, P > 0.05) and ''sexual relations'' (x 2 = 1.0, P > 0.05). After performing the Hochberg step-up test, no significant difference in the scores for both subscales was found between the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. Very low and low scores for the subscale ''health perceptions'' were obtained from 58.5% of the stigmatized patients and 24.4% of the patients with stigma, as opposed to 27.5% and 37.3% of the participants without perceived stigma (x 2 = 10.4, P < 0.01). High scores for the same subscale were obtained only from 2.4% of the stigmatized participants and 13.7% of the non-stigmatized participants. The correlation was moderate, and the reverse P < 0.01 (r s = À0.4). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. As for the subscale ''physical function'', 20% of the stigmatized participants gave very low scores and 25% gave low scores, as opposed to 5.7% and 11.3%, respectively, of the non-stigmatized patients (x 2 = 8.8, P < 0.01). High scores were obtained from 32.5%
of the stigmatized patients and from 49.1% of those without stigma. The correlation was moderate, and the reverse P < 0.01 (r s = À0.4). The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg step-up test, a significant difference in the scores for this subscale was demonstrated between the non-stigmatized and the mildly to moderately stigmatized patients.
According to the interviewed patients, the physical limitations in cases with perceived stigma were significant: 31.7% gave very low scores for this subscale, and 26.8% gave low scores, as opposed to 5.7% and 13.2%, respectively, of the non-stigmatized patients (x 2 = 17.2, P < 0.01). High scores were obtained from 31.7% of the stigmatized participants and from 62.3% of the non-stigmatized cases. The correlation was moderate, and the reverse P < 0.001 (r s = À0.5). The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg step-up test, a significant difference in the scores for this subscale was observed between the non-stigmatized and the severely stigmatized patients.
Perceived stigma correlated with a more frequent and a stronger feeling of pain (x 2 = 10.6, P < 0.05). Very low and low scores for this subscale were obtained from 33.3% and 20.5% of the stigmatized patients, and high scores were obtained from 28.2%. The non-stigmatized patients gave very low or low scores much more rarely -6.4% and 23.5%, respectively; the high assessments were much more frequent (46.8%). The correlation was moderate, and the reverse P < 0.01 (r s = À0.4). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. Perceived stigma had also an impact on the assessments of the subscale ''energy/fatigue'' (x 2 = 10.3, P < 0.01). The fatigue was perceived as significant by the stigmatized patients, as 24.2% of them gave very low scores, and 33.3% gave low scores for this subscale, as opposed to 2.0% and 38.8%, respectively, of the nonstigmatized patients. High scores were obtained from 18.2% of the stigmatized participants and from 30.6% of the non-stigmatized cases. The correlation was moderate, and the reverse P < 0.01 (r s = À0.4). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. The greatest influence of the perceived stigma on the subscale ''health discouragement'' was observed (x 2 = 26.1, P < 0.01).
Obviously, the negative attitude toward the patient and the disease determines a more pessimistic feeling for health status: 62.5% of the stigmatized participants gave very low scores, and 20.8% gave low scores for this subscale. High scores were obtained from 2.5% of the stigmatized participants and from 35.8% of the non-stigmatized cases. The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg stepup test, a significant difference in the scores for this subscale was observed among the non-stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. As a whole, the perceived stigma has a definite negative impact on most aspects of physical health, which is most likely associated with the suggestion of low self-esteem regarding the physical problems.
Impact of perceived stigma on mental health
Perceived stigma has an impact on all aspects of mental health.
It results in increased emotional limitations (x 2 = 13.6, P < 0.01). Only 15.4% of the non-stigmatized patients gave very low scores for the subscale ''emotional limitations'', as opposed to 42.5% of the stigmatized patients; 75.5% of the non-stigmatized participants and 48.5% of the stigmatized patients gave high scores. The correlation was significant, and the reverse P < 0.01 (r s = À0.5).
After performing the Hochberg step-up test, a significant difference in the scores for this subscale was observed between the nonstigmatized and the severely stigmatized patients. Perceived stigma also has a negative impact on the subscale ''emotional well-being'' (x 2 = 17.5, P < 0.01). There was a significant difference between the percentage of the non-stigmatized participants, with low scores for this subscale (29.2%), and the percentage of the stigmatized patients (71.5%): 27.1% of the non-stigmatized patients and 15.8% of the stigmatized patients gave high scores for this subscale. The correlation was moderate, and the reverse P < 0.01 (r s = À0.4). After performing the Hochberg step-up test, a significant difference in the scores for this subscale was observed between the non-stigmatized and the severely stigmatized patients. Perceived stigma also has a negative impact on the assessment of the following cognitive functions: attention/concentration (x 2 = 10.1, P < 0.01), memory (x 2 = 24.6, P < 0.01), and language (x 2 = 9.4, P < 0.05): 42.9% of the non-stigmatized patients gave high scores for the subscale ''attention/concentration'', as opposed to 13.9% of the stigmatized patients; 58.3% of the stigmatized participants and 31% of the non-stigmatized patients determined that these cognitive functions had been disturbed. The correlation was significant, and the reverse P < 0.01 (r s = À0.5). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. The percentage of stigmatized patients who gave very low and low scores for the subscale ''memory'' was 63.4%, as opposed to 12.8% of the non-stigmatized patients; 22% of the stigmatized participants and 46.8% of the non-stigmatized patients gave high scores for this subscale. The correlation was significant, and the reverse P < 0.01 (r s = À0.5). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
For the ''language'' subscale, 77.4% of the non-stigmatized patients and 47.5% of the stigmatized patients claimed that they did not have language problems: 11.4% of the non-stigmatized participants, compared with 22.5% of the stigmatized patients, gave very low and low scores. The correlation was moderate, and the reverse P < 0.05 (r s = À0.4). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
Impact of perceived stigma on social health
Perceived stigma influences all aspects of social health. The negative impact of perceived stigma on the assessment of the subscale ''work/driving/social function'' was demonstrated (x 2 = 26.5, P < 0.01): i.e., it is associated with limited opportunities for professional realization, driving and other social functions. Additionally, more severe stigma results in more limited social functions. The percentage of non-stigmatized patients who gave high scores for this subscale was 46.2%: in cases with mild to moderate stigma, it decreased to 7.1%, whereas none of the participants with severe stigma perceived these functions as preserved. Only 3.8% of the non-stigmatized participants, 7.1% of those with mild to moderate stigma, and 24% of the patients with severe stigma gave very low scores for this subscale. The correlation was significant, and the reverse P < 0.001 (r s = À0.5).
After performing the Hochberg step-up test, no significant difference in the scores for this subscale was observed among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. Perceived stigma has a negative impact on the assessment of the subscale ''social support'' as well (x 2 = 17.2, P < 0.01): i.e., it correlates directly with poorer social support. Additionally, more severe stigma results in poorer social support. The percentage of non-stigmatized patients who gave high scores for this subscale was 70%, but in cases with mild to moderate stigma, it decreased to 54.5%; 32% of the participants with severe stigma perceived the social support as sufficient. Only 4% of the non-stigmatized participants and 28% of the patients with severe stigma gave very low scores for this subscale. The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. Perceived stigma has a negative impact on the assessment of the subscale ''social isolation'' (x 2 = 25.1, P < 0.001): i.e., it correlates with more pronounced social isolation. More severe stigma results in more pronounced social isolation. The percentage of non-stigmatized patients who gave high scores for this subscale was 65.4%, but in cases with mild to moderate stigma, it decreased to 53.8%. Only 38.4% of the participants with severe stigma perceived the social isolation as lacking or poorly pronounced. Only 3.8% of the non-stigmatized participants and 43.5% of the patients with severe stigma gave very low scores for this subscale. The correlation was moderate, and the reverse P < 0.001 (r s = À0.4). The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg step-up test, a significant difference in the scores for this subscale was found among the non-stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
2.8. Impact of the perceived stigma on the quality of life aspects associated with epilepsy Perceived stigma has a negative impact on both aspects associated with epilepsy.
The stigmatized patients gave very low and low scores for the subscale ''medication effects'' much more frequently (39.4%) compared to the non-stigmatized patients (24.5%) [x 2 = 12.1,
26.3% of the stigmatized participants gave high scores compared to twice as many of the non-stigmatized patients (55.1%). After performing the Hochberg step-up test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
To assess the ''seizure worry'' subscale, 39.2% of the nonstigmatized patients and 52.9% of the stigmatized ones gave very low and low scores (x 2 = 13.3, P < 0.05). The percentage of nonstigmatized participants who gave high scores was much greater (39.2%) compared with the stigmatized patients (14.3%). The correlation was moderate, and the reverse P < 0.01 (r s = À0.3). These results prove that the perceived stigma correlates with more pronounced worries about seizures and side effects of antiepileptic drugs. The increase in stigma severity results in lower scores for the subscale ''seizure worry''. After performing the Hochberg stepup test, no significant difference in the scores for this subscale was found among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
2.9. Impact of perceived stigma on the subscales ''overall health'', ''overall quality of life'' and the overall score of QOLIE-89
Perceived stigma has a negative impact on the subscales ''overall health'' and ''overall quality of life'', as well as on the overall score of QOLIE-89.
Only 22.6% of the non-stigmatized patients gave very low and low scores for the subscale ''overall health'', compared with 28.5% of the participants with mild to moderate stigma and 62.9% of those with severe stigma (x 2 = 22.8, P < 0.01); 18.5% of the severely stigmatized patients gave high scores in contrast to the patients with mild to moderate stigma (28.6%) and the nonstigmatized patients (45.3%). The correlation was moderate, and the reverse P < 0.01 (r s = À0.4), i.e., more severe stigma results in lower scores for the subscale ''overall health.'' After performing the Hochberg step-up test, no significant difference in the scores for this subscale was observed among the stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients. As for the subscale ''overall quality of life'', 54.7% of the nonstigmatized patients gave very low and low scores compared with 66.7% of the participants with mild to moderate stigma and 90.9% of those with severe stigma (x 2 = 21.9, P < 0.01). None of the stigmatized patients gave similar scores, which contrasted with the non-stigmatized patients (17%). The correlation was significant, and the reverse P < 0.01 (r s = À0.5), i.e., more severe stigma results in lower scores for the subscale ''overall quality of life''. After performing the Hochberg step-up test, a significant difference in the scores for this subscale was observed between the nonstigmatized and the severely stigmatized patients.
As far as the overall score of QOLIE-89 is concerned, very low and low scores were calculated for 26% of the non-stigmatized patients, as well as 53.9% of the participants with mild stigma and 73.1% of the participants with severe stigma (x 2 = 21.9, P < 0.01).
High scores were calculated for 3.8% of the patients with severe stigma, but none were calculated for those with mild to moderate stigma and 46% of the non-stigmatized participants had high scores. The correlation was significant, and the reverse P < 0.01 (r s = À0.6). In conclusion, perceived stigma has an important negative impact: more severe stigma results in a lower overall QOLIE-89 score. The correlation was significant, and the reverse P < 0.001 (r s = À0.5). After performing the Hochberg step-up test, a significant difference in the scores for this subscale was found among the non-stigmatized, the mildly to moderately stigmatized, and the severely stigmatized patients.
Discussion
The purpose of this study was to assess the impact of perceived stigma on the quality of life of adult patients with refractory epilepsy. The obtained results have proven that perceived stigma correlates with lower scores for most subscales of QOLIE-89 (except for ''change in health'' and ''sexual relations''), as well as the overall score of QOLIE-89. The greatest percentage of stigmatized patients with very low and low scores was for the subscales ''health perceptions'' (82.9%), ''emotional well-being'' (71.5%), ''memory'' (63.4%), ''health discouragement'' (62.5%), ''role limitations -physical'' (58.5%), ''attention/concentration'' (58.3%), and ''energy/fatigue'' (57.5%). Regarding the assessment of the subscale ''overall quality of life'', 90.9% of the patients with severe stigma and 66.7% of those with mild and moderate stigma gave very low and low scores. Very low and low scores for the overall assessment of QOLIE-89 have been calculated for 73.1% of the patients with severe stigma and 53.9% of those with mild and moderate stigma. We have concluded that perceived stigma has a negative impact on all aspects of quality of life. There is a reverse correlation (from mild to significant): more severe stigma results in lower scores for the corresponding subscale. In the utmost degree, this correlation is valid for the subscale ''health discouragement'' P < 0.001 (r xy = À0.5) and the overall score of QOLIE-89 P < 0.01 (r xy = À0.6). Proofs about the negative impact of stigma on the quality of life have been found in the scientific literature as well. 6, 7 Whatley et al. have proven a similar negative correlation between stigma and quality of life P < 0.001 (r xy = À0.5) and have determined that stigma is a significant predictor of a decreased quality of life. 9 According to Salgado et al., stigma changes the patient's self-esteem and limits the available work opportunities; as a result, quality of life is significantly decreased. 
Limitations
The first limitation of our study is that we investigated perceived stigma of patients with refractory and pharmacosensitive epilepsy. Further investigations, not only on perceived stigma but also on enacted stigma, as well as an objective assessment of the attitude of Bulgarian society toward patients with epilepsy, are needed. Another limitation is that patients with refractory epilepsy completed QOLIE-89 because of the proven significant difference in stigma between the patients with RE and those with pharmacosensitive epilepsy. To adequately complete both the Stigma scale and QOLIE-89, we excluded patients older than 65 years, as well as those having cognitive impairment, progressive neurological disease, and those with either simple or complex partial seizures in the last 4 h or generalized tonic-clonic seizures in the last 24 h. The participation of only those patients that had access to the University Clinic of Neurology, as they usually attended it for either a regular examination or in cases of unsatisfactory seizure control or adverse events from treatment, is also a limitation. These limitations do not devalue the results from the first Bulgarian study of perceived stigma in patients with epilepsy and its impact on their quality of life. Further investigations of patients having different demographic, clinical and social characteristics are needed.
Conclusion
In conclusion the demonstration of the stigma role in decreased quality of life in patients with epilepsy contributes to the attention that this problem has drawn in Bulgaria, as well as all over the world, and illustrates the necessity of a multidisciplinary approach in dealing with these patients. Doing so will give us opportunities for a broader campaign, with the aim of ''getting epilepsy out of the shadows'' by increasing the role of epileptic patient associations, media, improving the education of medical and non-medical staff, and encouraging the government to give additional financial aid to patients and their families and invest in educational programs and research.
